Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272660 | 0.87 | SCN9A (0.32) | BTKNFKB1NFKB2RELA | |
| SCHEMBL24325886 | 0.87 | SCN9A (0.32) | BTKNFKB1NFKB2RELA | |
| SCHEMBL1151670 | 0.78 | EPHX1 (0.41) | BTKMEN1KMT2A | |
| SCHEMBL24325590 | 0.78 | MAPT (0.40) | BTKMEN1KMT2ANFKB1NFKB2 | |
| SCHEMBL24325888 | 0.75 | KAT2B (0.37) | BTK | |
| SCHEMBL26357191 | 0.73 | CHRM1 (0.32) | — | |
| SCHEMBL25273708 | 0.71 | KMT2A (0.48) | BTKMEN1KMT2A | |
| SCHEMBL24326572 | 0.71 | KMT2A (0.48) | BTKMEN1KMT2A | |
| SCHEMBL1374814 | 0.69 | DGAT1 (0.52) | MEN1KMT2A | |
| SCHEMBL28918296 | 0.69 | APLNR (0.40) | MEN1KMT2ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4192474-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | BTK 1556/4885MEN1 2721/4885MAPK1 1666/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | BTK 1556/4885MEN1 2721/4885MAPK1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.